QHSLab, Inc. 8K

QHSLab, Inc. reported strong fiscal 2025 results with higher revenue and margins, a shift to profitability, and substantial balance sheet strengthening through debt reduction and cash improvement.

QHSLab, Inc. (OTCQB: USAQ) announced its fiscal year 2025 results, reporting 26% revenue growth to approximately $2.69 million, higher gross profit and margin, and a swing to net income of about $457,000 from a prior-year loss, driven largely by strong expansion of its Integrated Service Program and increased immunotherapy sales. The company significantly improved its balance sheet by restructuring and extinguishing nearly all funded debt, recording roughly $1.15 million in gain on extinguishment of convertible debt, reducing current liabilities from about $2.4 million to $450,000, and increasing year-end cash to about $636,000. Management highlighted operational momentum and plans to further grow in 2026 through expansion of its physician network, scaling its digital health infrastructure, and emphasizing higher-margin, recurring digital health and allergy-related services.

Filing Facts

CIK

856984

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-013836

Alert Tier

6